Implications of Ghrelin and Hexarelin in Diabetes and Diabetes-associated Heart Diseases

Overview

Journal Endocrine

Specialty Endocrinology

Date 2015 Feb 4

PMID 25645463

Citations 10

Authors

Rasha Mofeed Habeeb Mosa

Zhen Zhang

Renfu Shao

Chao Deng

Jiezhong Chen

Chen Chen

Affiliations

Soon will be listed here.

Abstract

Ghrelin and its synthetic analog hexarelin are specific ligands of growth hormone secretagogue (GHS) receptor. GHS have strong growth hormone-releasing effect and other neuroendocrine activities such as stimulatory effects on prolactin and adrenocorticotropic hormone secretion. Recently, several studies have reported other beneficial functions of GHS that are independent of GH. Ghrelin and hexarelin, for examples, have been shown to exert GH-independent cardiovascular activity. Hexarelin has been reported to regulate peroxisome proliferator-activated receptor gamma (PPAR-γ) in macrophages and adipocytes. PPAR-γ is an important regulator of adipogenesis, lipid metabolism, and insulin sensitization. Ghrelin also shows protective effects on beta cells against lipotoxicity through activation of phosphatidylinositol-3 kinase/protein kinase B, c-Jun N-terminal kinase (JNK) inhibition, and nuclear exclusion of forkhead box protein O1. Acylated ghrelin (AG) and unacylated ghrelin (UAG) administration reduces glucose levels and increases insulin-producing beta cell number, and insulin secretion in pancreatectomized rats and in newborn rats treated with streptozotocin, suggesting a possible role of GHS in pancreatic regeneration. Therefore, the discovery of GHS has opened many new perspectives in endocrine, metabolic, and cardiovascular research areas, suggesting the possible therapeutic application in diabetes and diabetic complications especially diabetic cardiomyopathy. Here, we review the physiological roles of ghrelin and hexarelin in the protection and regeneration of beta cells and their roles in the regulation of insulin release, glucose, and fat metabolism and present their potential therapeutic effects in the treatment of diabetes and diabetic-associated heart diseases.

Citing Articles

[Correlation between serum ghrelin and liver-expressed antimicrobial peptide-2 with idiopathic short stature in children].

Liu Q, Zhang W, Chen B, Song Y Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(12):1261-1266.

PMID: 39725387 PMC: 11684832. DOI: 10.7499/j.issn.1008-8830.2404038.

Unlocking the Potential of Obestatin: A Novel Peptide Intervention for Skeletal Muscle Regeneration and Prevention of Atrophy.

Mitra A, Mandal S, Bose B, P S Mol Biotechnol. 2024; 66(5):948-959.

PMID: 38198052 DOI: 10.1007/s12033-023-01011-7.

LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity.

Lu X, Huang L, Huang Z, Feng D, Clark R, Chen C Front Endocrinol (Lausanne). 2021; 12:717544.

PMID: 34512549 PMC: 8428150. DOI: 10.3389/fendo.2021.717544.

Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data.

Camilleri M, Lembo A, McCallum R, Tourkodimitris S, Kemps L, Miller M Aliment Pharmacol Ther. 2020; 51(11):1139-1148.

PMID: 32301137 PMC: 7318559. DOI: 10.1111/apt.15711.

Growth Hormone Secretagogues and the Regulation of Calcium Signaling in Muscle.

Bresciani E, Rizzi L, Coco S, Molteni L, Meanti R, Locatelli V Int J Mol Sci. 2019; 20(18).

PMID: 31491959 PMC: 6769538. DOI: 10.3390/ijms20184361.

References

Guerlavais V, Boeglin D, Mousseaux D, Oiry C, Heitz A, Deghenghi R . New active series of growth hormone secretagogues. J Med Chem. 2003; 46(7):1191-203. DOI: 10.1021/jm020985q. View

Marleau S, Harb D, Bujold K, Avallone R, Iken K, Wang Y . EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J. 2005; 19(13):1869-71. DOI: 10.1096/fj.04-3253fje. View

Reimer M, Pacini G, Ahren B . Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology. 2003; 144(3):916-21. DOI: 10.1210/en.2002-220819. View

Halban P, Polonsky K, Bowden D, Hawkins M, Ling C, Mather K . β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care. 2014; 37(6):1751-8. PMC: 4179518. DOI: 10.2337/dc14-0396. View

Zhang C, Baffy G, Perret P, Krauss S, Peroni O, Grujic D . Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 2001; 105(6):745-55. DOI: 10.1016/s0092-8674(01)00378-6. View

Ghigo E, Aimaretti G, Arvat E, Camanni F . Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine. 2001; 15(1):29-38. DOI: 10.1385/ENDO:15:1:029. View

Anello M, Lupi R, Spampinato D, Piro S, Masini M, Boggi U . Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia. 2005; 48(2):282-9. DOI: 10.1007/s00125-004-1627-9. View

List J, Habener J . Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. Am J Physiol Endocrinol Metab. 2004; 286(6):E875-81. DOI: 10.1152/ajpendo.00007.2004. View

Ghigo E, Arvat E, Muccioli G, Camanni F . Growth hormone-releasing peptides. Eur J Endocrinol. 1997; 136(5):445-60. DOI: 10.1530/eje.0.1360445. View

10.

Bruning J, Michael M, Winnay J, Hayashi T, Horsch D, Accili D . A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell. 1998; 2(5):559-69. DOI: 10.1016/s1097-2765(00)80155-0. View

11.

Irako T, Akamizu T, Hosoda H, Iwakura H, Ariyasu H, Tojo K . Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats. Diabetologia. 2006; 49(6):1264-73. DOI: 10.1007/s00125-006-0226-3. View

12.

Aragno M, Mastrocola R, Ghe C, Arnoletti E, Bassino E, Alloatti G . Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms. Cardiovasc Diabetol. 2012; 11:129. PMC: 3537569. DOI: 10.1186/1475-2840-11-129. View

13.

Boyer J, Thanigaraj S, Schechtman K, Perez J . Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004; 93(7):870-5. DOI: 10.1016/j.amjcard.2003.12.026. View

14.

Verhagen S, Wassink A, van der Graaf Y, Gorter P, Visseren F . Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART study. Cardiovasc Diabetol. 2011; 10:100. PMC: 3268731. DOI: 10.1186/1475-2840-10-100. View

15.

Nagaya N, Kangawa K . Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr Opin Pharmacol. 2003; 3(2):146-51. DOI: 10.1016/s1471-4892(03)00013-4. View

16.

Granata R, Volante M, Settanni F, Gauna C, Ghe C, Annunziata M . Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J Mol Endocrinol. 2010; 45(1):9-17. DOI: 10.1677/JME-09-0141. View

17.

Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M . Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004; 89(11):5535-41. DOI: 10.1210/jc.2004-0150. View

18.

Kojima M, Kangawa K . Ghrelin: structure and function. Physiol Rev. 2005; 85(2):495-522. DOI: 10.1152/physrev.00012.2004. View

19.

Quan W, Jo E, Lee M . Role of pancreatic β-cell death and inflammation in diabetes. Diabetes Obes Metab. 2013; 15 Suppl 3:141-51. DOI: 10.1111/dom.12153. View

20.

Tschop M, Smiley D, Heiman M . Ghrelin induces adiposity in rodents. Nature. 2000; 407(6806):908-13. DOI: 10.1038/35038090. View